Protein trafficking dysfunctions: Role in the pathogenesis of pulmonary arterial hypertension

Pulmonary Circulation

Volumn 1, Issue 1, 2011, Pages 17-32

  Sehgal, Pravin B ^a   Lee, Jason E ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Golgi apparatus; Intracellular organelles; Pulmonary vascular remodeling

Indexed keywords

EID: 84863285704     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.78097     Document Type: Review

References (90)

1. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-32.
2. Sehgal PB, Mukhopadhyay S, Patel K, Xu F, Almodóvar S, Tuder RM, et al. Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques. Am J Physiol Lung Cell Mol Physiol 2009;297:L729-37.
3. Mathew R, Huang J, Shah M, Patel K, Gewitz M, Sehgal PB. Disruption of endothelial-cell caveolin-1alpha/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 2004;110:1499-506.
4. Zhao YY, Lui Y, Stan RV, Fan L, Gu Y, Dalton N, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A 2002;99:11375-80.
5. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 2009;119:2009-18.
6. Achcar RO, Demura Y, Rai PR, Taraseviciene-Stewart L, Kasper M, Voelkel NF, et al. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 2006;129:696-705.
7. Sehgal PB, Mukhopadhyay S. Pulmonary arterial hypertension: A disease of tethers, SNAREs, and SNAPs. Am J Physiol Heart Circ Physiol 2007;293:H77-85.
8. Sehgal PB, Mukhopadhyay S. Dysfunctional intracellular trafficking in the pathobiology of pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2007;37:31-7.
9. Bonifacino JS, Glick BS. The mechanisms of vesicle budding and fusion. Cell 2004;116:153-66.
10. Jahn R, Scheller RH. SNAREs—engines for membrane fusion. Nat Rev Mol Cell Biol 2006;7:631-43.
11. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signaling and turnover. Nat Cell Biol 2003;5:410-21.
12. Sehgal PB, Guo GG, Shah M, Kumar V, Patel K. Cytokine signaling: STATs in plasma membrane raft s. J Biol Chem 2002;277:12067-74.
13. Shah M, Patel K, Mukhopadhyay S, Xu F, Guo G, Sehgal PB. Membraneassociated STAT3 and PY-STAT3 in the cytoplasm. J Biol Chem 2006;281:7302-8.
14. Xu F, Mukhopadhyay S, Sehgal PB. Live cell imaging of interleukin-6-induced targeting of the “transcription factor” STAT3 to sequestering endosomes in the cytoplasm. Am J Physiol Cell Physiol 2007;293:C1374-82.
15. Mukhopadhyay S, Shah M, Xu F, Patel K, Tuder RM, Sehgal PB. Cytoplasmic provenance of STAT3 and PY-STAT3 in the endolysosomal compartments in pulmonary arterial endothelial and smooth muscle cells: Implication in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007;294:L449-68.
16. Le Borgne R. Regulation of Notch signaling by endocytosis and endosomal sorting. Curr Opin Cell Biol 2006;18:213-22.
17. Tuder RM, Marecki JC, Richter A, Fij lkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007;28:23-42.
18. Rabinovitch M. Molecular pathogenesis of pulmonary hypertension. J Clin Invest 2008;118:2372-9.
19. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361: 1533-44.
20. Morrell NW. Role of bone morphogenetic protein receptors in the development of pulmonary hypertension. Adv Exp Med Biol 2010;661: 251-64.
21. Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol Heart Circ Physiol 1997;41:H806-13.
22. Cajal SR. Algunas variaciones fisilógicas y patalógicas del aparato reticular de Golgi. Trab Del Lab De Inv Biol Madrid 1914;12:127-227.
23. Jaenke RS, Alexander AF. Fine structural alterations of bovine peripheral pulmonary arteries in hypoxia-induced hypertension. Am J Pathol 1973;73:377-98.
24. Meyrick B, Reid L. The effect of continued hypoxia on rat pulmonary arterial circulation. An ultrastructural study. Lab Invest 1978;38:188-200.
25. Meyrick B, Reid L. Hypoxia-induced structural changes in the media and adventitia of the rat hilar pulmonary artery and their regression. Am J Pathol 1980;100:151-78.
26. Smith P, Heath D. Electron microscopy of the plexiform lesion. Thorax 1979;34:177-86.
27. Heath D, Smith P, Gosney J, Mulcahy D, Fox K, Yacoub M, et al. The pathology of the early and late stages of primary pulmonary hypertension. Br Heart J 1987;58:204-13.
28. Smith P, Heath D, Yacoub M, Madden B, Caslin A, Gosney J. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 1990;160:111-21.
29. King AP, Smith P, Heath D. Ultrastructure of rat pulmonary arterioles aft er neonatal exposure to hypoxia and subsequent relief and treatment with monocrotaline. J Pathol 1995;177:71-81.
30. Mett e SA, Palevsky HI, Pietra GG, Williams TM, Bruder E, Prestipino AJ, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992;145:1196-200.
31. Harns PN, Anderson RC, Chen KK. The action of senecionine, integerrimine, jacobine, longilobine and spartiodine, especially on the liver. J Pharmacol Exp Ther 1942;69:69-77.
32. Harns PN, Anderson RC, Chen KK. The action of monocrotaline and retronecine. J Pharmacol Exp Ther 1942;75:78-82.
33. Bull LB. The histological evidence of liver damage from pyrrolizidene alkaloids: Megalocytosis of the liver cells and inclusion globules. Aust Vet J 1955;31:33-40.
34. Merkow L, Kleinerman J. An electron microscopic study of pulmonary vasculitis induced by monocrotaline. Lab Invest 1966;15:547-64.
35. Afzelius BA, Schoental R. The ultrastructure of the enlarged hepatocyes induced in rats with a single oral dose of retrorsine, a pyrrolozidine (Senecio) alkaloid. J Ultrastruct Res 1967;20:328-45.
36. Todorovich-Hunter L, Johnson DJ, Ranger P, Keeley FW, Rabinovitch M. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. A biochemical and ultrastructural study. Lab Invest 1988;58:184-95.
37. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 1988;255: H1484-91.
38. Sugita T, Stenmark KR, Wagner WW Jr, Henson PM, Henson JE, Hyers TM, et al. Abnormal alveolar cells in monocrotaline induced pulmonary hypertension. Exp Lung Res 1983;5:201-15.
39. Wilson DW, Segall HJ. Changes in type II cell populations in monocrotaline pneumotoxicity. Am. J. Pathol. 1990; 136:1293-1299.
40. Reindel JF, Roth RA. The effects of moncrotaline pyrrole on cultured bovine pulmonary artery endothelial smooth muscle cells. Am J Pathol 1991;138:707-19.
41. Lamé MW, Jones AD, Wilson DW, Dunston SK, Segall HJ. Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells. J Biol Chem 2000;275:29091-9.
42. Lamé MW, Jones AD, Wilson DW, Segall HJ. Monocrotaline pyrrole targets proteins with and without cysteine residues in the cytosol and membranes of human pulmonary artery endothelial cells. Proteomics 2005;5:4398-413.
43. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-4.
44. Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 2002;13:3055-63.
45. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002;11:1517-25.
46. Hong KH, Lee YJ, Lee E, Park SO, Han C, Beppu H, et al. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 2008;118:722-30.
47. West J. Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension. Adv Exp Med Biol 2010;661:265-78.
48. Razani B, Wang XB, Engelman JA, Batt ista M, Lagaud G, Zhang XL, et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without the disruption of caveolae. Mol Cell Biol 2002;22:2329-44.
49. Jasmin JF, Mercier I, Hnasko R, Cheung MW, Tanowitz HB, Dupuis J, et al. Lung remodeling and pulmonary hypertension aft er myocardial infarction: Pathogenic role of reduced caveolin expression. Cardiovasc Res 2004;63:747-55.
50. Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisante MP. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotalineinduced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006;114:912-20.
51. Marecki JC, Cool CD, Parr JE, Beckley VE, Luciw PA, Tarantal AF, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006;174:437-45.
52. Chaudhri R, Lindwasser OW, Smith WJ, Hurley JH, Bonifacino JS. CD4 downregulation by HIV-1 Nef is dependent on clathrin and involves a direct interaction of Nef with AP2 clathrin adaptor. J Virol 2007;81:3877-90.
53. Collett e Y, Aroid S, Picard C, Janvier K, Benichou S, Benarous R, et al. HIV-2 and SIV nef proteins target different src family SH3 domains than does HIV-1 Nef because of a triple amino acid substitution. J Biol Chem 2000;275:4171-6.
54. Hiyoshi M, Suzu S, Yoshidomi Y, Hassan R, Harada H, Sakashita N, et al. Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor. Blood 2008;111:243-50.
55. Roeth JF, Williams M, Kasper MR, Filzen TM, Collins KL. HIV-1 Nef disrupts MHC-1 trafficking by recruiting AP-1 to the MHC-1 cytoplasmic tail. J Cell Biol 2004;167:903-13.
56. Shah M, Patel K, Fried VA, Sehgal PB. Interactions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes. Preservation of cytokine signaling during fever. J Biol Chem 2002;277:45662-9.
57. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qui D, Pearl RG, et al. Simvastatin att enuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166: 1403-8.
58. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108:1640-5.
59. Shah M, Patel K, Sehgal PB. Monocrotaline pyrrole-induced endothelial cell megalocytosis involves a Golgi blockade mechanism. Am J Physiol Cell Physiol 2005;288:C850-62.
60. Mukhopadhyay S, Sehgal PB. Discordant regulatory changes in monocrotaline induced megalocytosis of lung arterial endothelial and alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006;290:L1216-26.
61. Mukhopadhyay S, Shah M, Patel K, Sehgal PB. Monocrotaline pyrroleinduced megalocytosis of lung and breast epithelial cells: Disruption of plasma membrane and Golgi dynamics and an enhanced unfolded protein response. Toxicol Appl Pharmacol 2006;211:209-20.
62. Sehgal PB, Mukhopadhyay S, Xu F, Patel K, Shah M. Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007;290:L1526-42.
63. Mukhopadhyay S, Xu F, Sehgal PB. Aberrant cytoplasmic sequestration of eNOS in endothelial cells aft er monocrotaline, hypoxia, and senescence: Live-cell caveolar and cyotplasmic NO imaging. Am J Physiol Heart Circ Physiol 2007;292:H1373-89.
64. Mukhopadhyay S, Lee J, Sehgal PB. Depletion of the ATPase NSF from Golgi membranes with hypo-S-nitrosylation of vasorelevant proteins in endothelial cells exposed to monocrotaline pyrrole. Am J Physiol Heart Circ Physiol 2008;295:H1943-55.
65. Ramos M, Lame MW, Segall HJ, Wilson DW. The BMP type II receptor is located in lipid raft s, including caveolae, of pulmonary endothelium in vivo and in vitro. Vasc Pharmacol 2006;44:50-9.
66. Wertz JW, Bauer PM. Caveolin-1 regulates BMPR II localization and signaling in vascular smooth muscle cells. Biochem Biophys Res Commun 2008;375:557-61.
67. Ramos M, Lame MW, Segall HJ, Wilson DW. Monocrotaline pyrrole induces Smad nuclear accumulation and altered signaling expression in human pulmonary arterial endothelial cells. Vasc Pharmacol 2007;46: 439-48.
68. Ramos MF, Lame MW, Segall HJ, Wilson DW. Smad signaling in the rat model of monocrotaline pulmonary hypertension. Toxicol Pathol 2008;36:311-20.
69. Sehgal PB. Paradigm shift s in the cell biology of STAT signaling. Semin Cell Dev Biol 2008;19:329-40.
70. Patel HH, Zhang S, Murray F, Suda RY, Head BP, Yokoyama U, et al. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB J 2007;21:2970-9.
71. Maximov A, Tang J, Yang X, Pang ZP, Sudhof TC. Complexin controls the force transfer from SNARE complexes to membranes in fusion. Science 2009;323:516-21.
72. Giraudo CG, Garcia-Diaz A, Eng WS, Chen Y, Hendrickson WA, Melia TJ, et al. Alternative zippering as an on-offswitch for SNARE-mediated fusion. Science 2009;323:512-6.
73. Matsushita K, Morrell CN, Cambein B, Yang SX, Yamakuchi M, Bao C, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethlymaleimide sensitive factor. Cell 2003;115:139-50.
74. Lee J, Reich R, Xu F, Sehgal PB. Golgi, trafficking, and mitotis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging. Am J Physiol Lung Cell Mol Physiol 2009;297:715-28.
75. Lee JE, Patel K, Almodovar S, Tuder RM, Flores SC, Dehgal PB. Dependence of Golgi apparatus on nitiric oxide in vascular cells; implications in pulmonary artirial hypertension. Am J Physiol Heart Circ Physiol 2011 [In Press].
76. Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, Rao J, et al. Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation 2010;121:98-109.
77. Orialo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J. Cell surfacebound IL 1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A 2009;106:17031-6.
78. Rodier F, Coppé JP, Patil CK, Hoeij makers WA, Muñoz DP, Raza SR, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009;11:973-9.
79. Almodovar S, Cicalini S, Petrosillo N, Flores SC. Pulmonary hypertension associated with HIV infection: Pulmonary vascular disease: The global perspective. Chest 2010;137:6S-12S.
80. Duffy P, Wang X, Lin PH, Yao Q, Chen C. HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells. J Surg Res 2009;156:257-64.
81. Yang X, Long Lu, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005;96:1053-63.
82. Sobolewski A, Rudarakanchana N, Upton PD, Yang J, Crilley TK, Trembath RC, et al. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: Potential for rescue. Hum Mol Genet 2008;17:3180-90.
83. Sakao S, Tanabe N, Tatsumi K. The estrogen paradox in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2010;299:L435-8.
84. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672-8.
85. Frank DB, Lowery J, Anderson L, Brink M, Reese J, de Caestecker M. Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol 2008;294:L98-109.
86. Farhat MY, Chen MF, Bhatt i T, Iqbal A, Cathapermal S, Ramwell PW. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br J Pharmacol 1993;110:719-23.
87. Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G. 2-methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol 2006;45:358-67.
88. Greenfield JP, Leung LW, Cai D, Kaasik K, Gross RS, Rodriguez-Boulan E, et al. Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis. J Biol Chem 2002;277:12128-36.
89. Hendrix EM, Myatt L, Sellers S, Russell PT, Larsen WJ. Steroid hormone regulation of rat myometrial gap junction formation: Effects on cx43 levels and trafficking. Biol Reprod 1995;52:547-60.
90. Dromparis P, Sutendra G, Michelakis ED. The role of mitochondria in pulmonary vascular remodeling. J Mol Med 2010;88:1003-10.